The significant role of tumor-associated neutrophils (TANs) in tumorigenesis is generally recognized. However, less is known about their polarization and the cytokines responsible for this process. Here, the authors report for the first time that type I interferons activate both mouse and human neutrophils and polarize them into pro-inflammatory anti-tumor phenotype with strong tumor cell killing capacities, facilitated partly by NETs formation. These findings reveal the potential of type I IFNs for an anti-cancer treatment. 
Introduction
The tumor microenvironment represents a special niche that massively influences invading immune cells. The concept of immune cell polarization, known already for macrophages (M1/M2) has been recently extended on neutrophils (TANs) (1) . We and others could previously demonstrate that TANs with pro-tumor phenotype (N2) accumulate during tumor progression and contribute to tumor growth by a plethora of mechanisms (2, 3, 4) e.g. via strong up-regulation of pro-angiogenic genes (VEGF, MMP9) possibly through activation of STAT3 and c-myc transcription factors. Additionally, we could show that pro-tumor neutrophils efficiently support metastatic processes, due to up-regulation of pro-metastatic proteins, like Bv8, MMP9, S100A8 and S100A9 (5) . Anti-tumor N1 neutrophils, in contrast, inhibit tumor growth (6) and are able to inhibit tumor seeding in the premetastatic lung via the generation of H 2 O 2 (9) or increase immune recognition of tumor cells through neutrophil elastase-dependent up-regulation of self-antigen presentation (10) . Furthermore, direct killing of tumor cells by such neutrophils, via the secretion of ROS has been demonstrated (11, own observation). Such TANs can also support adaptive anti-tumor immune responses by recruiting T cells to tumor sites via the secretion of chemokines like CXCL9 or CXCL10 (1, 12) . Interestingly, antigen-pulsed neutrophils have also been shown to cross-present antigens in vitro to activate cytotoxic T lymphocytes (CTLs) (13) .
Strict classification of TANs into N1 or N2 phenotypes is surely an oversimplification. More likely, these two immune-phenotypes mark the end points of a continuum of functional states that neutrophils exhibit. Our previous data revealed IFN-β as N1 promoting cytokine (4, 15, 16) and TGF-β has been suggested to be a N2 inducer (14) . In this manuscript, we provide further evidence emphasizing the involvement of type I IFNs in neutrophil polarization in tumor microenvironment. We demonstrate here for the first time the significant down-regulation of anti-tumor neutrophil markers, like ICAM1 and TNF-α in Ifnb1 -/-mice. In 4 agreement, we could also show the increase of ICAM1 expression on the neutrophils isolated from melanoma patients undergoing adjuvant type I IFN therapy. Type I interferon deficient neutrophils showed reduced formation of NETs, accompanied by lower tumor cell killing capacity. Under these conditions, massively enhanced neutrophil turnover in combination with accumulation of immature neutrophils was observed. Importantly, therapeutic intervention in mice using low dose IFN-β induced anti-tumor activation of neutrophils in tumors and in pre-metastatic lungs. Correspondingly, in human melanoma patients, neutrophil
anti-tumor characteristics were augmented upon type I IFN treatment and their migratory capacities reduced, suggesting an effective outcome of type I IFN therapy that should be further optimized in order to improve its therapeutic effect.
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Material and Methods
Animals
8 to 12 week old female mice were used. Ifnb1 -/-mice were backcrossed onto the C57BL/6 or BALB/c background for >15 generations. All mice were bred and kept under SPF conditions in the animal facility of the HZI (Braunschweig, Germany). 
Cell lines
Murine tumor models
Exponentially growing tumor cells were harvested and injected subcutaneously (s.c). Tumor sizes were evaluated by caliper and the volume was calculated: V = 4/3 x π x (h x w 2) / 8 (h = height and w = width).
Tumor depth= width.
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Low dose IFN-β β β β therapy of tumor-bearing mice
From day 3 after tumor cell inoculation, i.v. treatment with 1000 IU of recombinant mouse IFN-β (rmIFN-β) was performed every other day. After two weeks, mice were sacrificed and cells from blood, tumor and lung analyzed by flow cytometry.
Flow cytometry of cells from tumor, lung, blood and bone marrow
Tumor tissue was digested using dispase/collagenaseA/DNase suspension (0.2mg/ml 0.2mg/ml 100mg/ml). Cells were meshed through 50µm filters (Cell Trics, Partec), erythrocytes removed and single cell suspensions prepared.
Lungs were perfused through the right heart chamber using PBS, cut into pieces and digested as described above.
Erythrocytes from blood and bone marrow samples were removed.
Single cell suspensions were stained with antibodies listed above. To avoid unspecific binding of antibodies, cells were treated with anti-mouse CD16/CD32 antibodies.
For intracellular staining, cells were fixed/permeabilized using BD TM Cytofix-Cytoperm buffer. Flow cytometry was performed using BD LSRII system (BD Bioscience) and data analyzed using BD FACSDiva software (BD Bioscience).
Cell sorting
Single cell suspensions were prepared and stained. CD11b + Gr1 high or CD11b + Ly6G + neutrophils were sorted using a FACSAria TM cell sorter (BD Bioscience) and the purity of cells was assessed by reanalysis. Gating strategy for neutrophil staining and sorting is shown in Figure S3 BrdU labeling of bone marrow cells 
Cytospin analysis
Neutrophils were sorted, centrifuged onto Superfrost TM slides (Thermo Scientific), dried and stained with Giemsa solution (Sigma Aldrich). Nuclear morphology was assessed using light microscope (Zeiss). At least 10 fields of view were counted and percentage of immature ring shaped nuclei calculated. For human material ficoll purified blood neutrophils were treated as mentioned above and percentage of immature band shaped neutrophils was evaluated.
Visualization of NETs
Blood neutrophils were sorted as described above, distributed into Glass Bottom 96-well plates (MatTek Corporation, Ashland, USA) and incubated 3h with PMA (100 nM/well).
Subsequently, cells were fixed (4% paraformaldehyde, PFA), NETs stained using DNAhistone-H1-complex (Alexa 488) and MPO (Alexa 633), as previously described (51 
Human studies
Peripheral blood from melanoma patients was drawn into citrate tubes after written local ethics committee approval. All patients had no evidence of disease at the time of phlebotomy.
Patients from adjuvant interferon treatment group received recombinant interferon-alfa2 (3 million IU) three times/week. In all patients of the IFN group, blood was drawn during an ongoing adjuvant IFN treatment. Clinicopathological characteristics of patients enrolled in this study are listed in Supplementary Table 1 .
Isolation of human neutrophils
Peripheral blood from melanoma patients was drawn into 3.8% sodium citrate anticoagulant monovettes (Sarstedt), mixed with PBS (1:1, v/v) before separation by density gradient centrifugation (Biocoll density 1,077g/mL, Biochrom). The mononuclear cell fraction was discarded and neutrophils (purity > 98%) isolated by sedimentation over 1% polyvinyl alcohol followed by hypotonic lysis (0.2% NaCl) of erythrocytes.
Apoptosis assay
Spontaneous apoptosis of human neutrophils was determined by AnnexinV-PE apoptosis detection kit (BD Biosciences) after 24 hours culture in RPMI-1640 (Invitrogen)
supplemented with 10% FCS (Biochrom) and 1% (v/v) penicillin/streptomycin (Invitrogen).
Cells were analyzed on a BD FACSCanto II using DIVA 6.0 software.
Flow cytometry of human neutrophils
Neutrophils were stained using antibodies: anti-CD66b FITC (clone 802H3), anti-CD49d APC-Alexa 750 (clone HP2/1, Beckmann coulter), anti-CXCR1 PE (clone 8F1/CXCR1, 9 BioLegend), anti-CXCR2 PerCP-eFluor 710 (clone 5E8-C7-F10, eBioscience) and anti-CD54APC (clone HA58, eBioscience). To determine nonspecific signals, isotype controls were used at the same concentration as for the specific antibody.
Statistics
Statistical analyses were performed using a 1-tailed Student's t-test for single-value comparisons and one-way ANOVA to compare three or more different data sets. P < 0.05 was considered significant. Values are expressed as mean ± SEM.
Study approval
Mice studies have been approved by the regulatory authorities LAVES (33.9-42502-04-
13/1122 permission number).
Human studies have been approved by the appropriate institutional review board at the University of Duisburg-Essen, Essen, Germany. Written informed consent was received from participants prior to inclusion in the study. Additionally, the maturation status of circulating blood neutrophils was assessed using Giemsa staining. Interestingly, turnover and mobilization of Gr1 + CD11b + BrdU + neutrophils was significantly faster in the absence of endogenous IFN-β ( Fig.1) . A higher number of neutrophils entered the blood stream under such conditions ( Fig.1 A) . This was most likely due to the release of immature neutrophils into circulation in Ifnb1 -/-mice, since elevated numbers of neutrophils with a ring-shaped nucleus could be detected ( Fig.1 B-D) .
Results
Altered expression of co-stimulatory molecules and activation markers on Ifnb1 -/-TANs
One functional ability of neutrophils is the induction of an adaptive immune response (14) . To this end, neutrophils express different co-stimulatory molecules such as CD80, CD86 or ICAM1 (20), with ICAM1 being down-regulated on N2 pro-tumor neutrophils (21) . To elucidate the influence of endogenous IFN-β on the phenotype of TANs, we analyzed surface expression of ICAM1 on day 14 after s.c. inoculation of C57BL/6 mice with B16F10 melanoma cells or Balb/c mice using 4T1 breast carcinoma cells. Ifnb1 -/-versus WT animals were compared ( Fig. 2 A and B) . For blood neutrophils no significant differences were observed between the groups. In contrast, after neutrophil transmigration into the target tissue (tumor and lung) expression of ICAM1 was up-regulated. This up-regulation was reduced in the Ifnb1 -/-mice.
Besides ICAM1 up-regulation (22) the shedding of L-selectin CD62L is associated with neutrophil maturation and activation (23) . Therefore, CD62L expression on blood and tumor neutrophils was measured ( Fig.2 C and D) . Consistent with the observed accumulation of immature neutrophils in the circulation of tumor bearing Ifnb1 -/-animals ( Fig.1) , a significantly increased percentage of CD62L + neutrophils was detected in the blood of tumor bearing BALB/c Ifnb1 -/-mice (Fig.2 D) . In C57BL/6 mice, similar tendency could be observed (Fig. 2C) . Once neutrophils had migrated into the tumor tissue, CD62L expression seems not to depend on the presence or absence of endogenous IFN-β anymore ( Fig.2C and   D ).
Ifnb1 -/-neutrophils are clearly no myeloid derived suppressor cells (MDSCs)
In contrast to the immune stimulatory capabilities of N1 anti-tumor TANs, N2 pro-tumor TAN are reported to exert immunosuppressive function towards T cells (18) via inhibition of T cell responses by secretion of ROS (23) . To test whether the capability of blood and tumor neutrophils to suppress T cell proliferation is influenced by IFN-β, C57BL/6 and syngeneic
Ifnb1
-/-mice were challenged with B16F10 melanoma. After 14 days, neutrophils from different compartments were sorted out and incubated with CD4 + CD25 -T cells for 72h. After this time T cell proliferation was assessed. It could be shown that neutrophils sorted from different anatomical compartments of wild type or syngeneic Ifnb1 -/-tumor bearing mice stimulate rather than inhibit CD3 mediated T cell proliferation (Fig. S1 ).
Reduced tumor cell killing capacity of neutrophils isolated from Ifnb1 -/-mice
Besides their immunoregulatory functions, N1 neutrophils have the capacity to directly kill tumor cells (6) . This ability is reduced in N2 TAN (14) . To reveal the IFN-β impact on this phenomenon, neutrophil cytotoxicity from blood and tumors of BALB/c (Fig. 3A) or C57BL/6 (Fig. 3B) , and syngeneic Ifnb1 -/-animals was tested. Cells were sorted and cocultivated with luciferase expressing 4T1 tumor cells (effector:target ratio 2:1). To some cultures rmIFN-β was added. Luciferase activity, developing only in living cells, was measured after 18 hours of co-incubation, using IVIS200. Importantly, cytotoxicity of Ifnb1 -/-tumor neutrophils was significantly reduced, compared to WT ( Fig. 3A and B) , and could be restored by treatment with low amounts of rmIFN-β. The same was true for Balb/c, but not C57BL/6 blood neutrophils (Fig. 3A) . Moreover, TANs showed generally reduction of cytotoxicity in comparison to blood derived neutrophils, indicating further influence of the tumor microenvironment on neutrophil function. . Thus, endogenous IFN-β appears to support formation of NETs (Fig. 4) . These data are in agreement with the observed enhanced cytotoxicity of WT neutrophils against tumor cells.
Ifnb1
-/-tissue neutrophils produce reduced amounts of TNF-α α α α TNF-α is now known as important regulator of inflammation that can exert both, pro-tumor as well as anti-tumor functions, depending on its concentration (26) . The tumor toxic effect of TNF-α is not only due to direct cytotoxic or cytostatic effects on the tumor cells (27) , but can also be attributed to its immunostimulatory and vessel disrupting functions. In accordance, important feature of N1 neutrophils is the local production of TNF-α at tumor sites (14) . To elucidate the impact of endogenous IFN-β on neutrophilic TNF-α production, its expression in different anatomical compartments of WT and syngeneic Ifnb1 -/-animals was assessed. No significant differences regarding the percentage of TNF-α producing neutrophils were detected in peripheral blood ( Fig.S2 A and B) , but neutrophilic TNF-α production was remarkably increased after transmigration into the target tissue ( 
Low dose type I IFNs therapy induces N1 neutrophil phenotype in mice
High dose type I IFN therapy is currently used in the clinics to treat tumors, infections or autoimmune diseases. Treatment causes severe side effects in a dose-dependent manner that negatively influences patient compliance and often leads to the discontinuation of treatment (28, 29) . Therefore, it is of special interest to determine the effects of low dose type I IFN therapy on disease modifying aspects, like immune surveillance. For that reason, Ifnb1 -/-and WT mice were challenged with tumor cells and treated with low doses of IFN-β. On day 14 after tumor inoculation, neutrophilic phenotype was assessed by flow cytometry. IFN-β therapy indeed induced N1 neutrophil polarization. For C57BL/6 mice ( Fig.5 A) this was most profound for the adhesion molecule ICAM1, but also other markers showed a similar tendency. In BALB/c mice (Fig.5 B) , the N1 marker TNF-α and Caspase 3 were significantly 14 upregulated upon type I IFN treatment. Moreover, the extracellular N1 marker Fas as well as ICAM1 showed an increase, compared to untreated controls.
Metastasis i.e. the spread of tumor cells from the primary lesion to other non-adjacent organs is the fatal consequence of most malign tumors (30) . Even though the molecular mechanisms underlying metastasis formation are largely elusive to date, it is in the meantime recognized that establishment of a pre-metastatic niche is critical for this process (31) . Involvement of neutrophils in the formation of pre-metastatic niche has been suggested for lung metastasis (32) and we could show previously that type I IFNs were involved in the regulation of this processes (5). Therefore, we characterized the impact of type I IFNs on polarization of lung neutrophils. Mice were challenged with tumor cells that are known to form spontaneous lung metastases (33) and treated with low amounts of rmIFN-β for a period of 14 days. At given time points, polarization of lung neutrophils was analyzed ( Fig. 5 A and B) . In two mouse strains and both tumor models, low dose IFN-β therapy clearly induced an N1 polarization of neutrophils in the pre-metastatic lung (Fig. 5) . The expression of TNF-α and the activity of effector caspase 3 were significantly up-regulated. Similarly, ICAM1 and Fas were increased.
Neutrophil characteristics in melanoma patients are influenced by adjuvant type I IFN therapy
Even though the mechanisms responsible for the therapeutic effects of type I IFNs are not clearly defined, these cytokines are in clinical use as adjuvant treatment e.g. in high-risk melanoma patients (29) . Since type I IFN therapy in mice resulted in changes of neutrophil polarization, we wanted to corroborate these findings in the human system. Therefore, we analyzed neutrophil characteristics in human melanoma patients under type I IFN therapy and compared them to neutrophils from untreated control individuals. Importantly, spontaneous apoptosis of neutrophils isolated from type I IFN treated patients was increased (Fig. 6 A) and significantly more immature neutrophils were detected in the blood of these patients, 15 compared to controls (Fig 6 B) . Interestingly, percentage of CXCR2 expressing PMNs was not influenced (Fig. 6 C) , but chemotactic features of these cells, i.e. expression levels of the CXC chemokine receptors 1 and 2, were significantly reduced upon therapy (Fig. 6 D and E) .
Adjuvant type I IFN therapy seems also to influence ICAM1 expression levels (Fig.6 F) , but has no significant impact on tumor killing capacities of neutrophils (data not shown). All in all, these data suggest an important role of type I IFNs in neutrophil modulation not only in mice but also in man.
Discussion
Contribution of TANs to tumor angiogenesis, immunosurveillance and invasive growth is already well established by us and others (1,4), even though there are still some controversies regarding the differences between granulocytic myeloid-derived suppressor cells and TANs (34, 35) . Neutrophils represent an independent prognostic marker in a broad variety of neoplasias e.g. high number of intra-tumoral neutrophils in localized as well as metastatic renal cell carcinoma, correlates with a negative prognosis (36) . Therefore, TANs represent a Moreover, IFN-β has been demonstrated to inhibit the production of IL-17 by CD4 + T cells (38) . The prolonged life span of neutrophils in the absence of endogenous IFN-β is probably also responsible for an increased production of IL-23 by tissue macrophages, as the frequency of phagocytosis of dying neutrophils by macrophages limits the production of IL-23 (37) .
Previously, we could show that IFN-β is involved in the regulation of the life span (16), mobilization and turnover of mouse neutrophils via a plethora of different mechanisms.
Importantly, most of the pro-apoptotic neutrophil features (16) The secretion of TNF-α is another anti-tumor feature of neutrophils (14) . In this manuscript we show significant reduction of TNF-α expression in tumor and pre-metastatic lung neutrophils of Ifnb1 -/-mice, once again demonstrating tumor supportive activity of neutrophils in such mice. Importantly, TNF-α has been also demonstrated to induce neutrophil apoptosis (42) . Therefore, an elevated production of TNF-α by anti-tumor neutrophils observed in this manuscript is consistent with the shorter life span of such cells and its regulation by IFN-β.
The most prominent anti-tumor N1 neutrophil feature, i.e. their ability to directly kill tumor cells (2, 14) , seems also to be regulated by IFN-β. We observed that neutrophils isolated from blood or tumor of Ifnb1 -/-mice display significantly reduced tumor killing capacity in comparison to WT. Addition of rmIFN-β into the culture completely rescued the N1 phenotype, indicating the possibility to re-polarize neutrophils by therapeutic intervention.
This phenomenon was independent of mouse strain or tumor model used. 
